SuperworthCG Oncology revenue CGON
Sales by quarter and over the last twelve months, from 2023.
- Last 12 months, to Jun 30, 2026
- $6.2M
- Latest quarter, Q2 FY26
- $1.2M
- Fiscal year 2025
- $4M
- +255% on the year before
CG Oncology's revenue was $6.2M over the twelve months to Jun 30, 2026, up 1030% on a year earlier.
In its latest quarter, Q2 FY26, it was $1.2M.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $4M | +255% |
| FY2024 | $1.1M | +458% |
| FY2023 | $204K | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $1.2M | n/a | $6.2M | |
| Q1 FY26 | $1.1M | +1983% | $5.1M | |
| Q4 FY25 | $2.3M | +409% | $4M | |
| Q3 FY25 | $1.7M | +3774% | $2.2M | |
| Q2 FY25 | $0 | −100% | $551K | |
| Q1 FY25 | $52K | −90% | $662K | |
| Q4 FY24 | $456K | +45500% | $1.1M | |
| Q3 FY24 | $43K | +378% | $684K | |
| Q2 FY24 | $111K | n/a | $650K | |
| Q1 FY24 | $529K | +173% | $539K | |
| Q4 FY23 | $1K | n/a | $204K | |
| Q3 FY23 | $9K | n/a | n/a |
Against its peers
Companies in Biotechnology nearest CG Oncology's size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| CGONCG Oncology | $6.2M | |
| KRYSKrystal Biotech | $440.5M | +23% a year |
| RGENRepligen | $785.1M | +16% a year |
| TECHBIO-TECHNE | $1.2B | −0% a year |
| ADMAAdma Biologics | $512.3M | +8% a year |
| VCELVericel | $306.3M | +23% a year |
| HALOHalozyme Therapeutics | $1.7B | +41% a year |
| NBIXNeurocrine Biosciences | $3.4B | +34% a year |
| EXELExelixis | $2.4B | +9% a year |
| INCYIncyte | $5.8B | +27% a year |
| UTHRUnited Therapeutics | $3.2B | +2% a year |
| Peer median | $1.4B |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on CG Oncology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.